Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors by Maris A. Cinelli (1309419)

“…We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”

A647D decreased mexiletine sensitivity of P1332L when coexpressed. by Jie Liu (15128)

The effects of GM-CSF on DMN-induced histopathological changes. by Mrigendra Bir Karmacharya (13607415)

Subjects:

Effects of GM-CSF on the DMN-induced inhibition of PPAR-γ expression. by Mrigendra Bir Karmacharya (13607415)

Subjects:

Effects of GM-CSF on DMN-induced TGF-β1 expression. by Mrigendra Bir Karmacharya (13607415)

Subjects:

Western blot analysis of collagen type I, α-SMA, and TGF-β1 in liver. by Mrigendra Bir Karmacharya (13607415)

Subjects:

Effects of GM-CSF on DMN-induced hepatotoxicity. by Mrigendra Bir Karmacharya (13607415)

Subjects:

Effects of GM-CSF on DMN-induced changes in liver morphology, texture, and weight. by Mrigendra Bir Karmacharya (13607415)

Subjects:

Effects of GM-CSF on DMN-induced changes in survival and body weights. by Mrigendra Bir Karmacharya (13607415)

Subjects:

Fig 3 - by Yan Shu (441370)

DHT increases whereas orchidectomy decreases the weight and cross sectional area of hindlimb muscles. by Young-Eun Yoo (323357)

“…<b>A:</b> In WT mice, DHT increased the GN weight by 7% (212.4±8.8 mg), whereas orchidectomy decreased it by 14% (171.4±9.0 mg) compared with control WT mice (198.4±5.5 mg). …”

MMP-2 production is decreased following ALK5 inhibition. by Rebecca A. Scott (488956)

Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image3_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image7_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Table1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.xlsx by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

“…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”